13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neuroinflammation and Brain Disorders
Neuroinflammation is increasingly recognized as a key factor in the development and progression of a variety of brain disorders. Chronic neuroinflammation contributes to the breakdown of the blood-brain barrier and the accumulation of toxic proteins, leading to neuronal injury and loss. In the context of neuroinflammation and brain disorders, conditions such as Alzheimer's, Parkinson's, and autoimmune diseases like multiple sclerosis are significantly impacted by this inflammatory response. While initially protective, neuroinflammation can become maladaptive, further promoting brain damage. Advances in research are revealing the role of immune cells, such as microglia and T-cells, in driving neuroinflammation and how this process is directly linked to the progression of neuroinflammation and brain disorders. New therapies targeting neuroinflammatory pathways, including anti-inflammatory cytokines and microglial inhibitors, offer potential treatments to mitigate these effects and slow the progression of brain disorders.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States